WO1998028389A1 - Substance presentant une action anti-obesite, et une action reductrice de l'accumulation de graisse viscerale et utilisation de cette substance - Google Patents
Substance presentant une action anti-obesite, et une action reductrice de l'accumulation de graisse viscerale et utilisation de cette substance Download PDFInfo
- Publication number
- WO1998028389A1 WO1998028389A1 PCT/JP1997/004731 JP9704731W WO9828389A1 WO 1998028389 A1 WO1998028389 A1 WO 1998028389A1 JP 9704731 W JP9704731 W JP 9704731W WO 9828389 A1 WO9828389 A1 WO 9828389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fat
- substance
- oil
- visceral
- visceral fat
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 65
- 230000009278 visceral effect Effects 0.000 title claims abstract description 26
- 230000009471 action Effects 0.000 title abstract description 8
- 230000001186 cumulative effect Effects 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 210000001519 tissue Anatomy 0.000 claims abstract description 32
- 238000009825 accumulation Methods 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 150000002632 lipids Chemical class 0.000 claims abstract description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 claims abstract description 7
- 241000282414 Homo sapiens Species 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 65
- 235000019198 oils Nutrition 0.000 claims description 65
- 239000003925 fat Substances 0.000 claims description 55
- 235000019197 fats Nutrition 0.000 claims description 55
- 210000001593 brown adipocyte Anatomy 0.000 claims description 52
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 37
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 26
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 25
- 230000003579 anti-obesity Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 235000021323 fish oil Nutrition 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 244000124853 Perilla frutescens Species 0.000 claims description 16
- 235000004347 Perilla Nutrition 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 235000021388 linseed oil Nutrition 0.000 claims description 11
- 239000000944 linseed oil Substances 0.000 claims description 11
- 241000282412 Homo Species 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 235000021081 unsaturated fats Nutrition 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003486 adipose tissue brown Anatomy 0.000 abstract description 40
- 241000124008 Mammalia Species 0.000 abstract description 8
- 230000000476 thermogenic effect Effects 0.000 abstract description 5
- -1 for example Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 238000012360 testing method Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 235000020824 obesity Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000972773 Aulopiformes Species 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000019515 salmon Nutrition 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000000636 white adipocyte Anatomy 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000277331 Salmonidae Species 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002381 testicular Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 3
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 3
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000237502 Ostreidae Species 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000991 chicken egg Anatomy 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020636 oyster Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 2
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 2
- 101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101100048278 Rattus norvegicus Ucp1 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- NWCYECXHIYEBJE-UHFFFAOYSA-N 3-oxobutyl acetate Chemical compound CC(=O)CCOC(C)=O NWCYECXHIYEBJE-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000034525 diet induced thermogenesis Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000000209 wet digestion Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention specifically identifies uncoupled respiration (protonleak) of heat-producing tissue cells such as brown adipocytes (BA) in heat-producing tissues such as brown adipose tissue (BAT) in vivo. More specifically, the present invention relates to a substance derived from highly unsaturated fats and oils such as vegetable oils such as fish oil, linseed oil and perilla oil, A novel substance having an action of specifically enhancing the protein leak of heat-producing tissue cells such as brown adipocytes (BA) among living tissue cells of mammals including humans, said substance.
- Anti-obesity containing this substance as an active ingredient ⁇ Visceral accumulated fat reducing agent, Anti-obesity containing this substance as an active ingredient (inhibition of visceral fat accumulation) ⁇ Reduction of visceral fat accumulation Foods with the function Relates applications such as anti-obesity diets consisting denoted by the (visceral fat accumulation inhibition) within ⁇ product fat-lowering function comprising as an active ingredient o Background
- WA T white adipose tissue
- BAT brown adipose tissue
- WA White fat cells
- This WA breaks down triglycerides in the blood to supply fatty acids to fat cells and muscles.
- the latter brown adipose tissue is a tissue in which the body heat production function is highly developed, and in recent years, this brown adipose tissue is also involved in diet-induced body heat production when eating food, and It has become clear that deterioration is more likely to be associated with the onset of obesity (Toshihide Yoshida; Clinical Medicine for Obesity, Asakura Shoten, 21-31 (1993)).
- the metabolic activity related to the reduction of surplus fat accumulated in the living body: the reduction factor is the consumption required for basic metabolism as the activity energy of each organ of the living body, and the consumption of muscle tissue due to exercise.
- the brown adipose tissue is a tissue in which the body heat production function is highly developed as an aggregate of brown fat cells (BA), and has a heat production capacity of 300 to 400 W per kg of tissue. Having. Recently, the mechanism of body heat production by lipolysis of brown adipose tissue has been elucidated by molecular biology research, and for example, a so-called anti-obesity drug that directly stimulates brown fat cells to degrade fat Development research is being actively conducted by pharmaceutical manufacturers around the world (Kawata; , 8 5 (5), 5 5 3 (1 9 9 4))) o
- ob gene a free gene (ob gene) was cloned by Freedman et al. At Rockefeller University in the United States, and a protein called leptin was expressed by obgene in white adipocytes. It is secreted into the blood as tonic acid and acts on the hypothalamus of the brain, clearly controlling feeding behavior and the secretion of the adrenocortical hormone norepinephrine (NE). (JM Friedman et al., Nature, 372 (1 Dec.), 425-432 (1994), News Week, 12/14, p57 (1994)).
- Brown adipocytes contain an adrenergic receptor; 83 type (yS 3 —ADR), and it has been shown that ADR agonists via these receptors promote fat metabolism.
- the ADR agonist has been shown to act on brown adipocytes to increase potent lipolysis and body heat production.
- 3-Agonist (3-receptor agonist) is considered to be an effective anti-obesity drug for energy consumption, and very active research and development has been promoted.
- the anti-obesity drug aims to develop an S3-Agonist that directly acts on the norepinephrine receptor, and is already very effective in eliminating obesity in obese model animals.
- substances that operate on small animals have been developed by the US company AC C. (Kawata; Clinical and Nutrition, 85 (5), 553 (1994)), but still effective in humans. Agonist has not been found.
- peptides with specific structures can inhibit the differentiation of preadipocytes (PA) into adipocytes by oral administration. It has been confirmed that the fat accumulation in the body is suppressed by administration to rats (Japanese Patent Publication No. 5-87050, Japanese Patent Laid-Open No. Hei 6-2939796, Japanese Patent Laid-open No. Hei 7-18). 8 2 8 4).
- obesity is defined as obesity when fat is excessively accumulated in the body. From the viewpoint of energy balance, energy consumption greatly exceeds consumption and the body (visceral organs) as fat. It can be said that it is in a state of accumulation in large quantities. Depending on the location, bioaccumulated fat is classified into subcutaneous fat and visceral fat, and the nature of the former is difficult to accumulate and metabolized, whereas the latter is easy to accumulate. It has turned out to be quite different, such as being easily apologized. The reason that this visceral fat (obesity) is a multi-risk factor in the onset of adult disease is that fatty acids secreted from fat cells flow directly into the liver from the portal vein to enhance insulin resistance and lipogenesis.
- 83-Agonist is considered as an effective therapeutic agent for obesity for energy consumption, and very active research and development has been advanced. Thus, no effective Agonist has yet been found in humans.
- isolated soybean proteins and peptides activate brown adipose tissue to significantly reduce rat body fat, and peptides have a function to suppress blood triglyceride concentration increase. Has been obtained, but it has not been put to practical use.For example, the effectiveness of amino acid mixtures with the same composition as the target peptide has no effect. Are limited to those with a specific structure.
- dietary components that act on brown fat cells to induce body heat production are still limited to special spice components, etc., and do not fall within the range of ordinary food components.
- active ingredients having a function of strongly acting on heat-producing tissues such as brown adipose tissue to increase lipolysis and heat production, that is, heat-producing tissue cells such as brown adipocytes (BA) as active ingredients.
- heat-producing tissue cells such as brown adipocytes (BA) as active ingredients.
- the present invention provides the active ingredient (factor) having an action of acting on a heat-producing tissue cell such as a brown fat cell in a living body of a mammal including a human to specifically enhance the proton leak.
- a novel substance, a composition containing the substance, an anti-obesity containing the substance as an active ingredient (visceral organs) General processed foods, including foods for specified health use (functional foods) with a function of reducing visceral accumulated fat, visceral accumulated fat reducing agents, and anti-obesity containing the substance (factor) as an active ingredient And obesity.
- An object of the present invention is to provide a feed having a function of reducing visceral accumulated fat.
- the present inventors have conducted intensive studies with the aim of solving the above problems, and as a result, have found substances (factors) having the following specific effects, and have completed the present invention.
- the present invention includes the following technical means.
- Anti-obesity inhibition of visceral fat accumulation
- a substance having a function of specifically enhancing the proton leak of heat-producing tissue cells such as the brown adipocytes (BA) described above.
- Accumulated fat reducing agent a substance having a function of specifically enhancing the proton leak of heat-producing tissue cells such as the brown adipocytes (BA) described above.
- Anti-obesity containing, as an active ingredient, a substance having an effect of specifically enhancing the protein leak of heat-producing living tissue cells such as the brown fat cells (BA) described above. Inhibition) ⁇ Food PP o with visceral accumulated fat reduction function
- Prototypes of heat-producing tissue cells such as the aforementioned brown adipocytes (BA) Anti-obesity (suppressing visceral fat accumulation) containing a substance having a function of specifically enhancing leakage as an active ingredient ⁇ Feed that has a function of reducing visceral accumulated fat.
- BA brown adipocytes
- Anti-obesity suppressing visceral fat accumulation
- the substance having an action of specifically enhancing the protein leak of heat-producing tissue cells such as brown adipocytes, which is an active ingredient (factor) of the present invention is a substance present in natural lipids. It is artificially separated and refined.
- Raw materials for the above-mentioned substances (factors) of the present invention include natural lipids, especially highly unsaturated oils and fats which exist in nature, for example, fish oils and naturally derived vegetable oils such as linseed oil and perilla oil. Are preferred as examples, but the present invention is not particularly limited to these, and any equivalent or similar one can be used as appropriate, without being limited thereto.
- the above-mentioned substance (factor) of the present invention is a substance derived from the above-mentioned fats and oils, and those obtained by further purifying and fractionating the above-mentioned fats and oils as raw materials are also used as long as they have the same function. it can.
- a semi-refined or refined product having the above functions which has been refined by subjecting crude oil to further processes such as deoxidation, decolorization, and deodorization, is used. Further, a fraction having the above function obtained by the separation step is also used.
- the active ingredient (factor) of the present invention is used as an active ingredient in, for example, pharmaceuticals, foods, feeds, etc., it may be purified to an appropriate level according to its intended use.
- processed foods such as foods for specified health use (functional foods) are relatively refined, and when used for feed, the raw materials are natural fats and oils. It can be used.
- the active ingredient (factor) of the present invention is a substance derived from natural fats and oils such as the above-mentioned highly unsaturated fats and oils, but non-edible fats and oils are, for example, palm oil, coconut oil, soybean oil and the like. No This is evident from the fact that so-called common edible fats and oils have no effect.
- the UCP expression level of these substances was as high as 1.9 to 2.6 times that of the control.
- the active ingredient (factor) of the present invention is not limited to the oily substance derived from the above marine products, but may be a fraction, a purified product, a processed product, an extract, a mixture, or a composition as long as it has a similar function. (In the present invention, the composition and the like are defined as meaning these), and can be used in an appropriate form such as a similar substance obtained from the same kind of raw material.
- the active ingredient (factor) of the present invention has an effect of remarkably increasing the expression level of UCP in brown adipocytes, as described above. This suggests that it is effective in controlling visceral fat accumulation.
- the active ingredient (factor) of the present invention is present on the inner membrane of mitochondria (mit) in heat-producing tissue cells such as brown adipocytes (BA) involved in heat production in mammals including humans. It has the effect of increasing the expression level of uncoupled protein (UCP) and its homologues, and specifically enhancing the uncoupled respiration (proton leak) of the cells.
- the above-mentioned substance (factor) of the present invention is a substance whose structure is unknown. As described above, the substance significantly increases the expression level of UCP and its homologues in thermogenic tissue cells such as brown adipocytes. As a substance with high UCP expression, it can be identified, separated and purified using its expression activity as an index.
- thermogenic tissue cells such as the brown fat cells ( ⁇ ′ ′) refer to cells of thermogenic tissues such as brown fat, skeletal muscle and the immune system.
- the uncoupling protein (UCP) and its homologues are defined as protein subtypes (UC ⁇ 2 and UC ⁇ ) that are highly homologous to UC ⁇ and UC ⁇ and have a similar function. 3 etc.).
- a visceral accumulated fat reducing agent or a visceral fat accumulation inhibitor which is particularly effective for anti-obesity can be prepared.
- an appropriate filler, binder, extender, disintegrant, surfactant, dehumidifier, excipient, diluent may be used depending on the form of use. Can be used.
- the formulation may be appropriately determined according to the purpose of use, and is not particularly limited. Examples thereof include solids such as tablets, granules, powders, pills, and capsules; liquids, suspensions, and emulsions. And the like.
- the visceral accumulated fat reducing agent thus obtained can be administered by an appropriate administration method, and the dosage is appropriately selected according to the condition of the recipient. Therefore, the dose, the number of doses, and the like are not particularly limited.
- the above-mentioned various forms of the pharmaceutical preparation may be in an appropriate administration form such as injection administration and oral ingestion, and the administration route and administration site are not particularly limited.
- normal foods or foods for specified health use can be prepared using the above-mentioned substances (factors) of the present invention as active ingredients.
- the substance (factor) can be used as an additive for various foods.
- the types of foods mentioned above are not limited to foods for specified health use, but also include normal health foods, cakes, sweets, chocolate, Japanese sweets, meat products, fish meat products, cooked foods, etc. It can also be used for foods that use the same.
- the amount and form of the substance (factor) of the present invention in the food are appropriately selected according to the type of food, product concept, product form, and the like. Normally, it is exemplified that it is suitable to be blended in food at a level that allows intake of about 100 to 100 mg per single ingestion.o
- a feed having a function of suppressing visceral fat accumulation and a function of reducing visceral fat accumulation in livestock can be prepared.
- feed to which the above-mentioned substance of the present invention is blended for example, feed for livestock such as cows, pigs, chickens and the like are exemplified, and feed for livestock such as beef cattle is particularly preferable.
- the amount of the substance of the present invention to be added to the feed, the mixing form, and the like are appropriately selected according to the type of the feed, the livestock breeding situation, and the like. For example, if the feed is fed to beef cattle, ⁇ ⁇
- Figure 1 shows the UCP photo by the Western blot method. An example of the analysis of the work is shown below.
- FIG. 2 shows the UCP protein content in brown adipose tissue (BAT) protein.
- FIG. 3 shows the effect of promoting the expression of rat UCP-lmRNA by fish oil intake.
- Three-week-old male rats of the Sprague-Dawley strain were used, and the number of rats was 5 in each group. They were preliminarily reared for 1 week on a basic feed (F-2, Funabashi Farm Co., Ltd.).
- the breeding environment was adjusted to a temperature of 22 to 24 ° C and a humidity of 50 to 60%, and the light and darkness was set to a 12-hour cycle (light period: 8: 00 to 20: 00).
- the experimental feed consisted of the basic feed F-2, except for soybean white oil, instead of lard for lard, fish oil for fish oil (derived from bonito), amaji oil for amaji oil, and perilla oil for perilla. Oil (10% each was added and processed into pellets.
- the components of the feed used in the test are shown in Table 1, and the fatty acid composition of the raw fats and oils are shown in Table 2.
- Lard is oleic acid
- Fish oil is mainly composed of docosahexaenoic acid (DHA)
- linseed oil and perilla oil are mainly composed of monolinolenic acid, and feed and water are freely available, twice a week. The remaining food was removed and replaced, and food consumption and body weight were measured.
- Test feed ingredients (unit:%)
- body fat was measured using a scanner for measuring small animal body fat (CL-5351 type, manufactured by CLEACH Inc.). Blood was exsanguinated by cardiac puncture under nembutal anesthesia and sacrificed. Immediately, brown adipose tissue between the scapula and adipose tissue around the kidney and testis were collected and weighed. In addition, the brown adipose tissue was placed in a polytube, rapidly frozen in liquid nitrogen, and subjected to the measurement of uncoupling protein (U: C P) described below.
- uncoupling protein U: C P
- the BAT isolated from between the scapulae of the rat was homogenized with 30 OmM sucrose (1 OmM Tris — HCl, pH 7.5, containing 2 mM EDTA) and cooled with a tabletop centrifuge. After centrifugation at 3,100 rpm at 4 ° C. for 5 min, the supernatant was further centrifuged at 1,200 rpm at 4 ° C. for 10 min. The obtained precipitate (mitochondrial fraction) was used as a sample.
- Polyacrylamide gel electrophoresis was performed on a 11% separation gel, and 50 g of sample protein was analyzed for each line. The electrophoresis was performed at 100 V for 10 minutes, and then at 200 V for 1 hour. The transfer to the membrane (Hybond-C, manufactured by Amersham) was performed at 135 mA ( 2.5 mA / cm 2 ) for 30 minutes by a semidry method. Procking of the membrane was performed by immersion in a 1% skim milk solution for at least 1 hour. Next, the membrane is reacted with a rabbit antibody to rat UCP (primary antibody, diluted 1: 300), washed, and further labeled with rabbit ego IgG-peroxididase (secondary antibody). And reacted.
- a rabbit antibody to rat UCP primary antibody, diluted 1: 300
- rabbit ego IgG-peroxididase secondary antibody
- the Amani oil group was significantly less than the control lard group, and tended to be smaller in the fish oil group and the perilla oil group.
- the perinephric fat amount and the perirenal fat amount per body weight in the fish oil group were significantly lower than those in the control lard group, and tended to be lower in the linseed oil group and the perilla oil group.
- Figure 1 shows a rat UCP by the Western blot method. An example of the analysis of the BAT is shown below.
- Figure 2 and Table 4 show the UCP protein content in the protein as a percentage when the control lard was set to 100.
- the numbers represent the average soil standard deviation
- the visceral fat content was significantly reduced in the fish oil group, and the tendency was lower in the linseed oil and perilla oil.
- UCP uncoupling protein
- UCP-1 is the primary expression type in brown adipose tissue.
- mRNA was isolated from brown adipose tissue of mice fed a commercial solid feed (control group) or fish oil or lard, and probed with human UCP-1c DNA as in the previous experimental conditions.
- control group control group
- human UCP-1c DNA human UCP-1c DNA
- Example 1 As in Example 1 above, a 4-week-old male Sprague-Dawley male rat was preliminarily reared on a basal diet for 1 week, then divided into 10 groups as shown below for 7 animals per group and reared for 5 weeks. did.
- the breeding environment was the same as in Example 1, except that the feed was restricted and the body weight was measured weekly.
- Table 5 shows the basic composition of the feed used in the test.
- Lard control, commercially available
- Chicken egg yolk oil Bozen Kasei, oil and fat derived from egg yolk of chicken raised on feed containing fish oil, trade name: Active DHA-0
- Salmon egg Oil (4) trout egg oil, (5) salmon milt oil, (6) ⁇ milt oil, (7) hoyu testicular oil, (8) scallop ovary oil, (9) hoyu visceral oil, (1 0)
- Oyster offal oil was added at 9% each to prepare a test feed.
- Table 7 shows the measured values in each test group, with the control lard group as 100. There was no difference in body weight gain and feed intake between the test intervals. The UCP amount showed a surprisingly high value of 1.9 to 2.6 times that of the control in all the tested groups. Peritoneal fat, such as mesenteric fat, was significantly less or tended to be less. Similarly, serum lipid concentrations, such as triglycerides, were significantly lower or tended to be lower than the control lard group.
- Example 1 it was found that the marine-derived oily substance tested here significantly increased the expression of UCP in brown adipocytes and controlled the accumulation of intraperitoneal fat.
- the above-mentioned substance obtained by the present invention is a heat-producing tissue such as a brown fat cell (BA) in a heat-producing tissue such as a brown adipose tissue (.BAT) among cells in a living tissue such as a mammal including a human. It has the effect of specifically enhancing the cell leak of cells.
- anti-obesity suppression of visceral fat accumulation
- visceral accumulation fat reducing agent containing the substance as an active ingredient
- a composition containing the substance such as a composition containing the substance
- anti-obesity suppression of visceral fat accumulation
- a food having a function of reducing visceral accumulated fat an anti-obesity (inhibition of visceral fat accumulation) containing the substance as an active ingredient
- a feed having a function of reducing visceral accumulated fat.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Fats And Perfumes (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97949188A EP0947578A4 (en) | 1996-12-20 | 1997-12-19 | SUBSTANCE WITH ANTIOBESE AND CUMMULATIVE FABRIC REDUCING EFFECTS AND THEIR USE |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35493196 | 1996-12-20 | ||
JP8/354931 | 1996-12-20 | ||
JP9/293432 | 1997-10-09 | ||
JP9293432A JPH10231495A (ja) | 1996-12-20 | 1997-10-09 | 抗肥満および内臓蓄積脂肪低減化機能を有する物質、およびその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998028389A1 true WO1998028389A1 (fr) | 1998-07-02 |
Family
ID=26559410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004731 WO1998028389A1 (fr) | 1996-12-20 | 1997-12-19 | Substance presentant une action anti-obesite, et une action reductrice de l'accumulation de graisse viscerale et utilisation de cette substance |
Country Status (4)
Country | Link |
---|---|
US (1) | US20020009481A1 (ja) |
EP (1) | EP0947578A4 (ja) |
JP (1) | JPH10231495A (ja) |
WO (1) | WO1998028389A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012079A1 (fr) * | 1998-09-01 | 2000-03-09 | Janiftec, Inc. | Substances a fonction anti-obese et a fonction reduisant les graisses viscerales et utilisation de ces substances |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3607062B2 (ja) * | 1997-10-24 | 2005-01-05 | 株式会社コーセー | 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤 |
TWI329516B (en) | 2000-12-12 | 2010-09-01 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity |
IL155136A0 (en) * | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
JP2006347978A (ja) * | 2005-06-17 | 2006-12-28 | Nippon Flour Mills Co Ltd | 抗肥満剤及びこれを含む食品並びにペットフード |
JP4888687B2 (ja) * | 2005-09-29 | 2012-02-29 | マルトモ株式会社 | 免疫調節作用を有する化合物 |
JP5307424B2 (ja) * | 2008-03-16 | 2013-10-02 | 株式会社J−オイルミルズ | 腸管ホルモン分泌調整剤の製造方法、及び該製造方法で製造される腸管ホルモン分泌調整剤、並びにこれを含有する医薬 |
JP2011084546A (ja) * | 2009-09-15 | 2011-04-28 | Pharma Frontier Kk | 腸管ホルモン分泌調整成分の製造方法,使用方法,機能性食品および医薬 |
JP5581071B2 (ja) * | 2010-02-03 | 2014-08-27 | 花王株式会社 | ミトコンドリア機能向上剤 |
JP5718293B2 (ja) | 2011-09-15 | 2015-05-13 | 花王株式会社 | Gip上昇抑制剤 |
JP5863433B2 (ja) | 2011-10-07 | 2016-02-16 | 花王株式会社 | 油脂組成物 |
CN104601821B (zh) * | 2015-01-30 | 2018-09-21 | 江苏中航伟业电子科技发展有限公司 | 一种实现终端业务控制的方法 |
US20180153951A1 (en) * | 2016-12-05 | 2018-06-07 | Mead Johnson Nutrition Company | Methods for Inducing Adipocyte Browning, Improving Metabolic Flexibility, and Reducing Detrimental White Adipocyte Tissue Deposition and Dysfunction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6390598A (ja) * | 1986-10-03 | 1988-04-21 | 日本油脂株式会社 | ドコサヘキサエン酸を含む脂質の製造法 |
JPH0458847A (ja) * | 1990-06-23 | 1992-02-25 | Nippon Oil & Fats Co Ltd | 抗肥満症油脂および抗肥満症食品 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE47777B1 (en) * | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
JPH0324018A (ja) * | 1989-06-22 | 1991-02-01 | Tosoh Corp | 脂質代謝改善剤 |
JPH0750996A (ja) * | 1993-08-06 | 1995-02-28 | Baba Shiryo Kk | 家禽や家畜の給餌方法 |
JP3289165B2 (ja) * | 1994-03-01 | 2002-06-04 | 備前化成株式会社 | ドコサヘキサエン酸含有卵黄油の製造方法 |
JPH08325192A (ja) * | 1995-05-25 | 1996-12-10 | Bizen Kasei Kk | ドコサヘキサエン酸含有リン脂質の製造方法 |
-
1997
- 1997-10-09 JP JP9293432A patent/JPH10231495A/ja active Pending
- 1997-12-19 EP EP97949188A patent/EP0947578A4/en not_active Withdrawn
- 1997-12-19 WO PCT/JP1997/004731 patent/WO1998028389A1/ja not_active Application Discontinuation
- 1997-12-19 US US09/331,170 patent/US20020009481A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6390598A (ja) * | 1986-10-03 | 1988-04-21 | 日本油脂株式会社 | ドコサヘキサエン酸を含む脂質の製造法 |
JPH0458847A (ja) * | 1990-06-23 | 1992-02-25 | Nippon Oil & Fats Co Ltd | 抗肥満症油脂および抗肥満症食品 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0947578A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012079A1 (fr) * | 1998-09-01 | 2000-03-09 | Janiftec, Inc. | Substances a fonction anti-obese et a fonction reduisant les graisses viscerales et utilisation de ces substances |
Also Published As
Publication number | Publication date |
---|---|
EP0947578A1 (en) | 1999-10-06 |
JPH10231495A (ja) | 1998-09-02 |
US20020009481A1 (en) | 2002-01-24 |
EP0947578A4 (en) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2418350C (en) | Oil/fat composition | |
EP1430783B1 (en) | Oil/fat composition | |
JP2003047439A (ja) | 異性体濃縮共役リノール酸組成物の使用方法 | |
WO1998028389A1 (fr) | Substance presentant une action anti-obesite, et une action reductrice de l'accumulation de graisse viscerale et utilisation de cette substance | |
JP2008506774A (ja) | タンパク質材料と非酸化性脂肪酸体を含む組成物 | |
WO2007122801A1 (ja) | Gip分泌抑制剤 | |
KR20010079724A (ko) | 항 비만 및 내장축적지방 저감화기능을 보유하는 물질, 및그 용도 | |
WO2001091587A9 (en) | Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain | |
JP5718293B2 (ja) | Gip上昇抑制剤 | |
JP7023732B2 (ja) | 炎症を伴う肝疾患の治療または予防剤 | |
TW201642752A (zh) | 油摻合物、其製造方法及其於配方之用途 | |
JPH0542411B2 (ja) | ||
WO2010107325A1 (en) | Satiety product | |
JP4634065B2 (ja) | アディポネクチン低下抑制剤 | |
EP2298293A1 (en) | Lipase inhibitor | |
HU203660B (en) | Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids | |
JP2013063937A (ja) | Gip上昇抑制剤 | |
JPH0469614B2 (ja) | ||
JP2007099777A (ja) | 脂質代謝改善剤 | |
Idoko et al. | Physicochemical assessment of broiler chickens fed diets supplemented with a mixture of ginger, garlic and cinnamon | |
JPH04108360A (ja) | カルシウム吸収促進栄養剤、食品及び飼料 | |
Watanabe et al. | Digestion and absorption of diacylglycerol | |
JP6842093B2 (ja) | 学習記憶能力増強剤 | |
Hassanein et al. | Effects of dietary fish oil supplementation in the diet on performance of Broiler chicks | |
JP2006151875A (ja) | リパーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997949188 Country of ref document: EP Ref document number: 09331170 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997949188 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997949188 Country of ref document: EP |